Clinical Trial Update: Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease [Phase 4]

View source ↗

Summary

Phase 4 trial update comparing iGlarLixi vs iGlar on liver fat content in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatotic Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• iGlar (insulin glargine)
• iGlarLixi (insulin glargine + lixisenatide)

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease, Diabetes Mellitus Type 2 | Phase 4 | Status: ENROLLING_BY_INVITATION